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Simple Summary: Raman spectroscopy, a light scattering technique which provides the biochemical
fingerprint of a sample, was used on samples taken from patients with cancer and precancerous
lesions. This information was then used to build a classifier to identify cancer and the precancerous
phases. The ability to distinguish cancerous tissue from normal and precancerous tissue is
diagnostically crucial as it can alter the patients’ prognosis and management. Moreover, as cellular
changes are often present at the tumour margin, the ability to distinguish these changes from cancer
can help in preserving more of the tissue and maintaining aesthetics and functionality for the patient.
Abstract: Early diagnosis, treatment and/or surveillance of oral premalignant lesions are important in
preventing progression to oral squamous cell carcinoma (OSCC). The current gold standard is
through histopathological diagnosis, which is limited by inter and intra observer and sampling errors.
The objective of this work was to use Raman spectroscopy to discriminate between benign, mild,
moderate and severe dysplasia and OSCC in formalin fixed paraffin preserved (FFPP) tissues. The
study included 72 different pathologies from which 17 were benign lesions, 20 mildly dysplastic, 20
moderately dysplastic, 10 severely dysplastic and 5 invasive OSCC. The glass substrate and paraffin
wax background were digitally removed and PLSDA with LOPO cross-validation was used to
differentiate the pathologies. OSCC could be differentiated from the other pathologies with an
accuracy of 70%, while the accuracy of the classifier for benign, moderate and severe dysplasia was
~60%. The accuracy of the classifier was lowest for mild dysplasia (~46%). The main discriminating
features were increased nucleic acid contributions and decreased protein and lipid contributions in
the epithelium and decreased collagen contributions in the connective tissue. Smoking and the
presence of inflammation were found to significantly influence the Raman classification with
respective accuracies of 76% and 94%.
Keywords: Oral cancer, Oral pre-cancer, Oral dysplasia, premalignant lesions, potentially malignant
lesions, Raman Spectroscopy.
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1.Introduction
Oral cancer (OC) is the 16th most common cancer worldwide, 354,864 new cases and 177,384
deaths having been reported in 2018 [1]. Over 90% of oral cancers are squamous cell carcinomas
affecting the tongue, floor of the mouth, lips, gingivae, buccal mucosa and palate. The major risk factors
for developing oral cancer are smoking and alcohol consumption, which can work synergistically [24]. Premalignant lesions such as leukoplakia (white patch) and erythroplakia (red patch) carry an
increased risk of malignant transformation [5]. Different degrees of dysplasia can be found in the
premalignant lesions which are classified into hyperplasia, mild, moderate and severe dysplasia and
carcinoma in situ, depending on the degree of architectural disturbance and cytologic atypia [5].
Generally, 5-25% of oral leukoplakia are dysplastic, while almost all erythroplakia show some degree
of dysplasia [5]. Despite advances in therapeutic management, there has been no significant
improvement in the 5 year survival rate of OC, which remains at around 50% [6]. This, in part, is due
to the fact that over 40% of patients present at an advanced stage, at which nodal involvement and
distant metastasis have occurred [7]. This highlights the importance of early diagnosis. Currently the
gold standard for diagnosing OC and dysplasia is through a conventional clinical oral examination,
followed by a biopsy of any suspicious lesions and their histopathological examination [8]. The issue
with this method is that it is subjective and prone to inter and intra observer errors [9]. Additionally, a
biopsy may not be representative of the whole lesion, as studies looking at the histology of tumours
post operatively and comparing them to the preoperative biopsies have found that, in a significant
number of cases, a neoplasia or carcinoma in-situ was misdiagnosed [10].
Raman Spectroscopy is a technique that was developed based on the Raman effect. When electromagnetic (EM) radiation interacts with a sample, it may be absorbed, or scattered. While most scattering
is elastic, named Rayleigh scatter, the Raman effect describes the inelastic scattering that occurs in a
small number of photons (about 1 in a million), which lose or gain energy by interaction with the
material vibrations. The Raman scattered light can be collected by a spectrometer and displayed as a
Raman spectrum, in which the peaks (bands) correspond to Raman frequency shifts (measured in
wavenumbers cm-1) caused by the characteristic vibrations in the molecules of a sample. There has been
a lot of interest in the use of Raman spectroscopy in medical diagnostics since its introduction to the
field almost 30 years ago [11]. Its advantages, such as minimal sample preparation, speed, noninvasiveness, label free nature, and the fact that it gives both qualitative and quantitative information
on the molecular content of a sample make it particularly suited to such applications. Over the past 20
years, there have been numerous studies in the area of Raman spectroscopy for diagnosis of a wide
range of cancers, including breast, lung, prostate, cervical, oesophageal and colon (reviewed in [12-16].)
These studies demonstrate that Raman Spectroscopy can be used to distinguish the different stages in
the progression of a cell from normal to cancerous. Monitoring cancer progression after the withdrawal
of carcinogens is another avenue that has been explored using Raman Spectroscopy [17]. In addition,
Raman spectroscopy has recently been shown to have potential for screening for metastases [18, 19]
and for companion diagnostics [20]. There have been several studies on Raman spectroscopy for oral
cancer, and the state of the art and challenges have been recently reviewed [21]. Notably, however,
there has been very little work on oral dysplasia or oral pre-cancer. Using OSCC and dysplastic cell
lines and comparing them to normal cells, a study has found that Raman spectroscopy could
discriminate between malignant, dysplastic and normal cells in the fingerprint region based on varying
nucleic acid, protein and lipid profiles [22]. Similar results were obtained from the high wavenumber
region of the spectrum [23]. Studies on fresh and frozen tongue tissue sections could classify OSCC
from normal tissue using Raman spectroscopy with a high degree of accuracy [24-27]. Analysis of the
water content in the high wavenumber region of spectra obtained in OSCC bone resection margins,
classified OSCC from healthy tissue with 95% accuracy [28]. Nevertheless, a study looking at surgical
margins in sections of OSCC found that the accuracy of the Raman classification for dysplastic tissue
was only 48% [29].
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In the present study, we aimed to assess whether Raman spectroscopy can discriminate between
benign lesions, different degrees of dysplasia and OSCC from the biopsied tissues of a cohort of patients
and to evaluate the influence of patient factors and clinical features on the Raman spectra of the tissues.

2. Results
2.1 Epithelial tissue
Figure 1 (A) shows the mean Raman spectra of epithelial tissue in each cohort. Table 1 lists the
concurrent peak assignments [30].

(A)

(B)

(C)

(D)

Figure 1 (A) Mean Raman spectra of benign, mild, moderate and severely dysplastic epithelial tissue. The
spectra have been offset for clarity and shading denotes standard deviation (B) A plot of the PLSDA scores
according to LV-1 (C) Mean and standard deviation of PLSDA scores of LV-1 (D) LV-1 of the PLSDA model
for Epithelial tissue, including all the classes.

Cancers 2020, 12, x FOR PEER REVIEW

4 of 19

Table 1 Tentative peak assignments, adapted from Movasaghi et al. [30]

Wavenumber (cm-1)
484-90
599/600
666
752
782
811/12
814
838
855
919
934/935
937/8
1001/2
1030-34
1128/9
1131
1237
1245-8
1265
1278
1285
1315-17
1333
1336
1368
1373
1437
1441
1449/50
1460
1554
1572-78
1650
1652-55
1666-8
1674
1700-50

Assignment
Glycogen
Nucleotide conformation
G,T (ring breathing modes in DNA bases)
Symmetric breathing mode of tryptophan
DNA
RNA O-P-O stretch
C-C stretching (collagen assignment)
Deformative vibrations of amine groups
Ring breathing in tyrosine/C-C stretching in proline
C-C stretch of Proline ring/ glucose lactic acid C-C, proline ring
(collagen assignment)
Protein/C-C backbone (collagen assignment)
Proline, hydroxyproline (C-C) skeletal of collagen backbone
Phenylalanine ring breathing
Phenylalanine of collagen
Skeletal C-C stretch in lipids
Fatty acid
Amide III
Amide III of collagen
Amide III
Proteins including collagen I
Differences in collagen
Guanine
Guanine
Polynucleotide chain (DNA purine bases)
Guanine TRP protein, porphrin, lipids
T,A,G (ring breathing modes of the DNA/RNA bases)
CH2 deformation (lipid)
Wax
C-H vibration lipids
CH2/CH3 deformation in Lipids
Amide II
Guanine adenine
Amide I
Lipid C=C (lipids) / Amide I
Protein / collagen
C=C stretch in cholesterol
Amino acids aspartic and glutamic acid

The results of the partial least squares discriminant analysis (PLSDA) classification do not show a very
good discrimination across the groups (Table 2). The estimated ROC curves are based on predicted
class for each spectrum. Sensitivity is calculated from the fraction of in-class spectra while the specificity
is calculated from the fraction of not-in-class spectra for a given threshold. The cross validated ROC
curves follow the same method, except the class predicted when the spectra are left out during cross
validation is used. From the ROC curves (Supplementary Error! Reference source not found. 1), it
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appears that the classifier has the highest accuracy for SCC (AUC=0.71) and lowest for mildly dysplastic
epithelium (AUC=0.46).
Table 2 Sensitivity and specificity values obtained from PLSDA classification with LOPOCV*

Epithelium
Sensitivity (%)

Connective Tissue

Specificity (%)

Sensitivity (%)

Specificity (%)

Benign

74

49

81

44

Mild

67

38

67

46

Moderate

39

86

42

61

Severe

69

57

59

67

SCC

65

76

88

72

LOPOCV*= Leave one patient out cross validation

To better elucidate the variability between the different classes, their scores on the first latent variable
(LV-1) were plotted. This shows a large intra-class spread, the greatest spread being observed in the
moderate group and the smallest in the SCC group (Error! Reference source not found. (B)). Plotting
the means and standard deviations of the scores on LV-1 (Error! Reference source not found.1 (C))
does not show an obvious progression, but it can be assumed from their means that the benign and
mild are mostly negative for LV-1, while moderate, severe and SCC are mostly positive . LV-1 (Figure
1 (D)), which is reponsible for 26.23% of the variance, has positive peaks at 783, 1371 and 1576 cm-1,
which relate to nucleic acids (Error! Reference source not found.1). Negative peaks are observed at
934, and 1282 cm-1 (relating to protein/collagen) and the amide 1 band at 1650 cm -1.
2.2 Connective tissue

From their mean spectra (Figure 2(A)), the most notable difference between benign, mild,
moderate, severe and SCC connective tissue appears to be in the regions 800-1000 cm-1 which
correspond to different collagen assignments and 1200-1400 cm-1 which correspond to vibrations in
lipids, nucleic acid bases, and collagen (Table 1). The results of the PLSDA classification (Table 2) show
high sensitivities for benign and SCC compared to the dysplasia classes. However, the specificity for
benign was low, indicating a high false positive rate. The classifier has the best accuracy among the
classes for SCC according to the ROC curve (Supplementary Figure 2).
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(A)

(B)

(C)

(D)

Figure 2 (A) Mean Raman spectra of benign, mild, moderate severely dysplastic and SCC connective tissue.
The spectra have been offset for clarity and shading denotes standard deviation (B) A plot of the PLSDA
scores of LV-1 (C) Mean and standard deviation of PLSDA scores of LV-1 (D) Loading of LV-1 of the PLSDA
model which included all the classes.

Plotting the scores of LV-1 shows the greatest intra-class spread in the mild group and the smallest in
the SCC group (Error! Reference source not found. 2 (B)). Plotting the means and standard deviations
of the scores of LV-1 (2 (C)) shows a progression from benign to SCC on LV-1. The means of the benign
and mild are negative in LV-1 while those of moderate, severe and SCC are positive.
Positive peaks of LV-1 can be observed at 1005, 1131, 1218, 1337, 1435 and 1581 cm-1 LV-1 (Error!
Reference source not found.2 (D)). The peaks at 1005 and 1581 cm-1 relate to phenylalanine, while those
at 1131, 1218 and 1435 cm-1 relate to lipids and that at 1337 cm-1 relates to nucleic acids. On the other
hand, negative peaks can be observed at 811, 855, 938, 1241, 1453 and 1672 cm -1. The peaks at 855, 938
and 1241 cm-1 relate to collagen while 1453 and 1672 cm-1 relate to lipid contributions.
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2.3 Influence of patient factors and clinical features on Raman classification
Other factors which could have an influence on the Raman classification were assessed. Metadata was
used to divide all the patients, regardless of histopathological diagnosis, into groups according to
gender, smoking habits, alcohol consumption, site of lesion and presence of inflammation. Two factors
were found to influence the Raman classification, namely smoking and the presence of inflammation.
2.3.1 Smoking
The patients were divided into 3 groups according to smoking status; non-smoker, ex-smoker (previous
smokers) and smoker (table 3).
Table 3 Sensitivity and specificity values from PLSDA with LOPOCV for smoking status in epithelium

Non smoker
(n=13)

Ex-smoker
(n=17)

Smoker
(n=13)

Sensitivity (%)

83

81

52

Specificity (%)

46

38

88

The PLSDA results showed high classification sensitivity for non-smokers and ex-smokers but lower
specificities. On the other hand, the classification sensitivity was lower for smokers but the specificity
was higher (Table 3). The ROC curve (Supplementary Figure 3) shows a significant accuracy
(AUC=0.76) of the classifier for smokers.

(A)

(B)

Figure 3 (A) Scores of Smokers and Non-smoker/Ex-smokers on the latent variables from the PLSDA model.
(B) Loading of LV-1 from PLSDA of Smokers vs Non-smoker and Ex-smokers in epithelial tissue.

To further understand the source of the variance, non-smokers and ex-smokers were combined and the
scores of LV-1 and LV-2 were plotted against those for smokers (Figure 3 (A)). While there is some
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overlap, smokers are mainly negative in LV-1, while non-smoker/ex-smokers are mainly positive.
According to LV-1, negative bands at 667, 784, 1372, and 1573 cm-1 suggest higher levels of nucleic acids
in the epithelium of smokers. Non-smoker/ex-smokers had a more prominent amide I band at 1651 cm1 and protein band at 934 cm-1 (Figure 3 (B)).

2.3.2 Presence of inflammation;
All the pathologies were evaluated for the presence of inflammation, indicated by the presence
of inflammatory infiltrate with chiefly lymphocytes and mast cells. The H&E stained slides were
evaluated under a bright-field microscope. Table 4 shows the number of inflamed samples per class.
PLSDA was used to classify inflamed vs non-inflamed for all the pathologies combined. The results
show that inflamed tissue can be classified from non-inflamed tissue with sensitivity and specificity
values of 68% and 70%, respectively, in epithelium and 77% and 86%, respectively, in connective tissue.
The AUCs were significant, 0.72 for epithelium and 0.84 for connective tissue (Supplementary figure
4).
Table 4 Number of inflamed samples per class

Class

Benign
(n=17)

Mild
(n=20)

Moderate
(n=20)

Severe
(n=10)

SCC
(n=5)

Number
Inflamed

2

3

9

7

5

To ensure that the results obtained are due to the presence of inflammation rather than the pathology
(as most of the severe and SCC samples were inflamed, which could skew the results), inflamed vs noninflamed was assessed in the moderate category. The results show a very high accuracy in connective
tissue (AUC=0.94) and, to a lesser extent, in epithelium (AUC=0.69) (Supplementary figure 5). Plotting
the scores of the latent variables shows a good separation based on LV-1, the majority of inflamed
spectra have negative scores while the majority of non-inflamed spectra have positive scores on LV-1
(Error! Reference source not found.). The group of non-inflamed spectra that are outside the 95%
confidence interval are likely from one patient who was misclassified due to increased variability from
the rest of the non-inflamed group. The loading of LV-1 (Error! Reference source not found.4(B)) shows
positive peaks at 813, 855, 939, 1031, and 1245 cm-1 which relate to collagen (Error! Reference source
not found.), while the negative peaks relate to nucleic acids (1334, 1580 cm-1) and fatty acids (1132, 1438
cm-1).
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(B)

Figure 4 (A) Scores of inflamed and non-inflamed moderately dysplastic connective tissue on the latent
variables from the PLSDA model. (B) Loading of LV-1 from the PLSDA model of inflamed vs non-inflamed
connective tissue.

3. Discussion
Raman spectroscopy can uncover a wealth of biochemical information including the lipid,
protein and nucleic acid content of the tissue, which in turn can reflect the presence and degree of tissue
pathology.
The choice to study each part of the tissue (epithelium and connective tissue) independently was made
in order to better understand/identify the changes taking place in each. While it was expected to find
discrimination between severe, mild and moderate in the epithelium, as the epithelial cells are
undergoing morphological and biochemical changes, significant differences in connective tissue
between the pathologies were not expected.
Results from the PLSDA show increasing nucleic acid contributions and lower protein and lipid
contributions as dysplasia progresses in the epithelium. According to the ROC curves, the accuracy of
the classifier was highest for the SCC class (AUC=0.71), intermediate (AUC ~0.6) for the benign,
moderate and severe classes, and lowest (AUC=0.46) for the mild, resulting in misclassification with
benign and moderate. The moderate group had the lowest sensitivity in the PLSDA classification and
the greatest spread in LV-1, suggesting a higher variability in this group compared to the others. It is
important to note that these classifications are based on histological grading by one pathologist,
whereas Raman spectroscopy measures the biochemical composition of the sample. Hence incipient
biochemical changes before the onset of tissue morphological changes might be influencing the
classification.
In connective tissue, nucleic acid peaks were more prominent with progressive dysplasia and collagen
peaks were less prominent. Connective tissue associated with SCC could be classified from that
associated with dysplasia and with benign lesions with a high sensitivity and specificity. This is to be
expected as, due to epithelial mesenchymal transition [31]; the boundary between epithelium and
connective tissue in SCC is often lost as a result of islands of epithelium invading the connective tissue
[32].
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From the results, it is apparent that some factors other than the degree of dysplasia can influence the
Raman classification. While it has been reported that age related physiological changes can be
discriminated with Raman spectroscopy [33],[34], most of the patients in this cohort were between 5060 years old, and hence there was not enough variation to study age related factors. No discrimination
based on gender was apparent; the female vs male sensitivity and specificity values in epithelium were
22% and 77%, respectively. In connective tissue, the sensitivity was 62% and specificity was 44%
(Supplementary figure 6). Other patient factors and clinical features which have not been considered,
due to lack of metadata, could potentially have an influence on the Raman classification. These include
HPV and candida status of the patients, the size of the lesions, and the degree of differentiation in the
SCC lesions.
Smoking status was seen to impact on the classification of epithelial tissue (AUC=0.76). This is
consistent with previous work by Singh et al., who have shown that the oral buccal mucosa of smokers
is more likely to misclassify with that of premalignant lesions than that of non-smokers [33], [35]. This
is likely due to the fact that smoking is an aetiological factor in developing oral dysplasia, and hence
biochemical changes occurring in the mucosa of smokers are similar to those occurring in dysplastic
lesions.
The presence of inflammation in connective tissue, however, was found to have a significant influence
on the Raman classification (AUC=0.94). Reduced collagen features and increased nucleic acid features
in the Raman spectra of inflamed connective tissue were the main findings and this has been previously
shown for cervical tissue [36]. The nucleic acid features may be due to increased cellularity caused by
the inflammatory cells infiltrating the tissue. The reduction of collagen features is likely due to the
breakdown of collagen by matrix metalloproteinases (especially MMP-8) which are upregulated in
inflammation [37]. In this study, most of the severely dysplastic and SCC tissue was found to be
inflamed, which is consistent with a previous study that has shown increasing inflammatory cell
infiltration with increasing severity of oral dysplasia and SCC [38]. The presence of inflammation in the
tumour microenvironment has been well documented and is due to multiple factors [39], [40]. The
environmental factors that prompt carcinogenesis, such as alcohol and smoking, have been shown to
trigger an inflammatory response [41]. Furthermore, the tumour cells release inflammatory mediators
which generate an inflammatory microenvironment that promotes cancer growth, invasion and
metastasis [42]. A study looking at OSCC surgical margins found that inflamed connective tissue was
more likely to misclassify with SCC than non-inflamed connective tissue [29].
4.Materials and Methods
4.1 Sample Preparation
Archival oral formalin fixed paraffin preserved (FFPP) tissues for each patient cohort were
obtained following ethical approval from St James’ Hospital Ethics Committee and informed written
consent from patients. The haematoxylin and eosin (H&E) stained sections from the different
pathologies were examined by a pathologist and the areas of interest were annotated. In total, 57
patients were included, from which 72 pathologies were identified. 17 benign lesions, 20 mildly
dysplastic, 20 moderately dysplastic, 10 severely dysplastic and 5 invasive SCC. The FFPP tissue blocks
and corresponding images were then taken to the laboratory, where 10 µm sections were cut from the
FFPP tissues and mounted on glass slides. One of the sections from each sample was dewaxed, stained
with H&E (Figure 5), and a parallel unstained section was used for Raman spectroscopic measurement.
4.2 Instrumentation
A confocal, Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope
(Figure 6) was used to record the spectra of the FFPP oral tissue. The microscope has an automated xyz
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stage and is coupled to a Peltier cooled CCD detector. A 50 mW diode laser of 532 nm wavelength was
used and the grating was set at 600 grooves/mm, while the confocal hole was set at the recommended
100 µm. For mapping acquisition, the regions to map were selected using a 100X objective (MPLAN N
Olympus, Japan, NA=0.9, spot size ~1m), which also collected the backscattered light. The spectra
were acquired over two accumulations, totalling 20 seconds per spectrum. The step size was set at 10
µm and the spectral range was 400-1800 cm-1. For every pathology section, 200 spectral points were
taken from epithelium and the same from connective tissue.
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(A)
mod

Severe
dysplasia

mild

(B)

(C)

Figure 5 Representative H&E images showing (A) the regions of dysplasia marked by the pathologist. (B)
A magnified region of moderate dysplasia (C) A magnified region of severe dysplasia
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Figure 6 A schematic of a Raman microspectrometer based on the Horiba Jobin Yvon LabRAM HR 800

4.3 Data Analysis
All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox
(Eigenvector Research Inc.) and in-house algorithms. Two quality control steps were employed (Figure
7). In the first, before processing, spectra with excess scatter/background were eliminated by setting a
maximum intensity. Subsequent processing involved smoothing with a Savitsky Golay filter (5th order,
13 points) then correcting the baseline with a rubberband function, and finally vector normalisation.
The second quality control step involved removing the spectra with excess wax and low biological
content. This was achieved using k-means clustering which is used to partition data into groups such
that variation is minimised within groups but maximised between groups. It assigns data points to
their closest centre points which are changed with each iteration until optimal convergence is met. The
next step was digitally subtracting the wax and glass backgrounds; which was carried out using the
non-negatively constrained least squares fitting (NNLS) method. A PCA of the epithelium and
connective tissue has demonstrated that the primary (~60%) variance of spectra of both FFPP tissue
types derives from the contribution of the paraffin wax [43]. Therefore, for a detailed analysis of the
more subtle biochemical origins of potentially malignancy, the contributions of the paraffin to the
spectra were removed. A matrix of 300 wax and glass spectra were used as inputs for the NNLS along
with spectra of pure cell components such as DNA and RNA. Using a matrix, instead of a mean
spectrum, accounts for the inhomogeneity in the wax spectra which is a result of the microcrystalline
domains being randomly oriented with respect to the laser source [43].
Partial least squares discriminant analysis (PLSDA) was used to build the classifier. It is a supervised
form of multivariate analysis which works as a linear classifier that aims to separate the data into
groups using a hyperplane. It is a generalisation of multiple linear regression (MLR), in which a set of
dependent variables y is regressed against independent predictor variables X. Similar to linear
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discriminate analysis (LDA), it aims to maximise the variance between groups and minimise the
variance within groups. It is based on partial least Squares Regression (PLSR). Whereas, in classic PLSR,
y is a matrix of continuous variables, in PLSDA it is categorical and used to assign the observations into
classes. The data was divided into y classes from 1 to 5, corresponding to benign, mild, moderate and
severe dysplasia and SCC. Similar y class assignments were made according to gender, smoking status
etc. The loadings of the discriminate hyperplanes or latent variables (LV)s were plotted to give more
information on the source of the variance. While it is similar to other statistical methods such as PCA,
the PLSDA LVs are calculated to maximise the covariance between the spectral variation and
group/category so that the LVs explain the diagnostically relevant variations rather than the most
prominent variations in the spectral dataset. Leave one patient out cross validation (LOPOCV) was
used as a cross validation method to avoid overtraining the model. In LOPOCV, the spectra of all but
one patient are used as a training set and a prediction is made for the left out patient. This is repeated
so that the spectra of each patient are left out and predicted once.
Receiver operating characteristic (ROC) curves were plotted for each class. ROCs are a plot of the true
positive rate (sensitivity) against the false positive rate (1 - specificity) over a continuous range (from 0
to 1) of cut off points of a classifier. Each point on the ROC curve represents a sensitivity/specificity pair
corresponding to a particular decision threshold. Accuracy is measured by the area under the ROC
curve (AUC), so that, the closer the curve tends to the left and top borders, the more accurate the
classifier. Conversely, the closer the curve is to the diagonal (baseline), the higher the misclassification
rate and the lower the accuracy. The baseline is at 0.5, while a perfect classifier would have an AUC of
1. In general, an AUC of 0.5 is considered to have no discrimination, while 0.7 to 0.8 is considered
acceptable, 0.8 to 0.9 is considered excellent, while over 0.9 is considered outstanding [44]. Different
approaches to estimate the ROC curve lead to different estimates of the AUC. Both the estimated AUC
(using the whole dataset) and cross validated AUC (leaving one patient dataset out in each iteration)
are shown.
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Figure 7 Spectral processing steps (A) Raw spectra. (B) Spectra after first quality control step, smoothing,
baseline correction and normalization. (C) Spectra after k-means grouping; the spectra in red have high wax
and low biological content while those in blue have higher biological content and less wax. (D) Spectra after
glass and wax subtraction.

5. Conclusions
The finding that Raman spectroscopy can differentiate between cancer and dysplasia is very
important, as the management and prognosis is different for both. Dysplasia is a common finding in
tumour borders and regenerative changes which mimic dysplasia can often be found in the margins of
resected tumours [45]. The balance between being conservative and maintaining as much of the tissue
as possible, which is important both aesthetically and functionally, and removing enough of the tumour
to prohibit recurrence is a difficult one in oral cancer surgery. Hence the ability of Raman spectroscopy
to discriminate between cancerous and dysplastic and/or healthy tissue can be important in striking
that balance. The finding that smoking and the presence of inflammation have a significant impact on
the Raman classification highlights the importance of accounting for these variables in any future
studies to be able to develop more robust diagnostic algorithms.

Cancers 2020, 12, x FOR PEER REVIEW

16 of 19

References

1.
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A., Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. Ca-a Cancer Journal for Clinicians 2018, 68 (6), 394-424.
2.
Pfeifer, G. P.; Denissenko, M. F.; Olivier, M.; Tretyakova, N.; Hecht, S. S.; Hainaut,
P., Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated
cancers. Oncogene 2002, 21 (48), 7435-7451.
3.
Boffetta, P.; Hashibe, M., Alcohol and cancer. Lancet Oncology 2006, 7 (2), 149-156.
4.
Hashibe, M.; Brennan, P.; Chuang, S. C.; Boccia, S.; Castellsague, X.; Chen, C.;
Curado, M. P.; Dal Maso, L.; Daudt, A. W.; Fabianova, E.; Fernandez, L.; Wunsch-Filho,
V.; Franceschi, S.; Hayes, R. B.; Herrero, R.; Kelsey, K.; Koifman, S.; La Vecchia, C.;
Lazarus, P.; Levi, F.; Lence, J. J.; Mates, D.; Matos, E.; Menezes, A.; McClean, M. D.;
Muscat, J.; Eluf-Neto, J.; Olshan, A. F.; Purdue, M.; Rudnai, P.; Schwartz, S. M.; Smith,
E.; Sturgis, E. M.; Szeszenia-Dabrowska, N.; Talamini, R.; Wei, Q. Y.; Winn, D. M.;
Shangina, O.; Pilarska, A.; Zhang, Z. F.; Ferro, G.; Berthiller, J.; Boffetta, P., Interaction
between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in
the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiology
Biomarkers & Prevention 2009, 18 (2), 541-550.
5.
van der Waal, I., Potentially malignant disorders of the oral and oropharyngeal mucosa;
terminology, classification and present concepts of management. Oral Oncology 2009, 45 (45), 317-323.
6.
Silverman, S., Demographics and occurrence of oral and pharyngeal cancers - The
outcomes, the trends, the challenge. Journal of the American Dental Association 2001, 132,
7S-11S.
7.
Marur, S.; Forastiere, A. A., Head and neck cancer: Changing epidemiology, diagnosis,
and treatment. Mayo Clinic Proceedings 2008, 83 (4), 489-501.
8.
Poh, C. F.; Ng, S.; Berean, K. W.; Williams, P. M.; Rosin, M. P.; Zhang, L. W.,
Biopsy and histopathologic diagnosis of oral premalignant and malignant lesions. Journal of
the Canadian Dental Association 2008, 74 (3), 283-288.
9.
Abbey, L. M.; Kaugars, G. E.; Gunsolley, J. C.; Burns, J. C.; Page, D. G.; Svirsky,
J. A.; Eisenberg, E.; Krutchkoff, D. J.; Cushing, M., INTRAEXAMINER AND
INTEREXAMINER RELIABILITY IN THE DIAGNOSIS OF ORAL EPITHELIAL
DYSPLASIA. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics
1995, 80 (2), 188-191.
10.
Scully, C., Challenges in predicting which oral mucosal potentially malignant disease
will progress to neoplasia. Oral Diseases 2014, 20 (1), 1-5.
11.
Puppels, G. J.; Demul, F. F. M.; Otto, C.; Greve, J.; Robertnicoud, M.; Arndtjovin,
D. J.; Jovin, T. M., STUDYING SINGLE LIVING CELLS AND CHROMOSOMES BY
CONFOCAL RAMAN MICROSPECTROSCOPY. Nature 1990, 347 (6290), 301-303.
12.
Jermyn, M.; Desroches, J.; Aubertin, K.; St-Arnaud, K.; Madore, W. J.; De
Montigny, E.; Guiot, M. C.; Trudel, D.; Wilson, B. C.; Petrecca, K.; Leblond, F., A review
of Raman spectroscopy advances with an emphasis on clinical translation challenges in
oncology. Physics in Medicine and Biology 2016, 61 (23), R370-R400.
13.
Santos, I. P.; Barroso, E. M.; Schut, T. C. B.; Caspers, P. J.; van Lanschot, C. G. F.;
Choi, D. H.; van der Kamp, M. F.; Smits, R. W. H.; van Doorn, R.; Verdijk, R. M.; Hegt,
V. N.; von der Thusen, J. H.; van Deurzen, C. H. M.; Koppert, L. B.; van Leenders, G.;
Ewing-Graham, P. C.; van Doorn, H. C.; Dirven, C. M. F.; Busstra, M. B.; Hardillo, J.;

Cancers 2020, 12, x FOR PEER REVIEW

17 of 19

Sewnaik, A.; ten Hove, I.; Mast, H.; Monserez, D. A.; Meeuwis, C.; Nijsten, T.; Wolvius,
E. B.; de Jong, R. J. B.; Puppels, G. J.; Koljenovic, S., Raman spectroscopy for cancer
detection and cancer surgery guidance: translation to the clinics. Analyst 2017, 142 (17), 30253047.
14.
Upchurch, E.; Isabelle, M.; Lloyd, G. R.; Kendall, C.; Barr, H., An update on the use
of Raman spectroscopy in molecular cancer diagnostics: current challenges and further
prospects. Expert Review of Molecular Diagnostics 2018, 18 (3), 245-258.
15.
Hiremath, G.; Locke, A.; Sivakumar, A.; Thomas, G.; Mahadevan-Jansen, A., Clinical
translational application of Raman spectroscopy to advance Benchside biochemical
characterization to bedside diagnosis of esophageal diseases. Journal of Gastroenterology and
Hepatology 2019, 34 (11), 1911-1921.
16.
Hubbard, T. J. E.; Shore, A.; Stone, N., Raman spectroscopy for rapid intra-operative
margin analysis of surgically excised tumour specimens. Analyst 2019, 144 (22), 6479-6496.
17.
Kumar, P.; Ingle, A.; Krishna, C. M. In In vivo Raman spectroscopy: monitoring
cancer progression post carcinogen withdrawal, Conference on Optical Imaging,
Therapeutics, and Advanced Technology in Head and Neck Surgery and Otolaryngology, San
Francisco, CA, Feb 02; San Francisco, CA, 2019.
18.
Santana-Codina, N.; Marce-Grau, A.; Muixi, L.; Nieva, C.; Marro, M.; Sebastian,
D.; Munoz, J. P.; Zorzano, A.; Sierra, A., GRP94 Is Involved in the Lipid Phenotype of Brain
Metastatic Cells. International Journal of Molecular Sciences 2019, 20 (16).
19.
Chrabaszcz, K.; Kochan, K.; Fedorowicz, A.; Jasztal, A.; Buczek, E.; Leslie, L. S.;
Bhargava, R.; Malek, K.; Chlopicki, S.; Marzec, K. M., FT-IR- and Raman-based biochemical
profiling of the early stage of pulmonary metastasis of breast cancer in mice. Analyst 2018, 143
(9), 2042-2050.
20.
Farhane, Z.; Nawaz, H.; Bonnier, F.; Byrne, H. J., In vitro label-free screening of
chemotherapeutic drugs using Raman microspectroscopy: Towards a new paradigm of
spectralomics. Journal of Biophotonics 2018, 11 (3).
21.
Sahu, A.; Krishna, C. M., Optical diagnostics in oral cancer: An update on Raman
spectroscopic applications. Journal of Cancer Research and Therapeutics 2017, 13 (6), 908915.
22.
Carvalho, L.; Bonnier, F.; O'Callaghan, K.; O'Sullivan, J.; Flint, S.; Byrne, H. J.;
Lyng, F. M., Raman micro-spectroscopy for rapid screening of oral squamous cell carcinoma.
Experimental and Molecular Pathology 2015, 98 (3), 502-509.
23.
Carvalho, L.; Bonnier, F.; Tellez, C.; dos Santos, L.; O'Callaghan, K.; O'Sullivan,
J.; Soares, L. E. S.; Flint, S.; Martin, A. A.; Lyng, F. M.; Byrne, H. J., Raman spectroscopic
analysis of oral cells in the high wavenumber region. Experimental and Molecular Pathology
2017, 103 (3), 255-262.
24.
Yu, M. X.; Yan, H.; Xia, J. B.; Zhu, L. Q.; Zhang, T.; Zhu, Z. H.; Lou, X. P.; Sun,
G. K.; Dong, M. L., Deep convolutional neural networks for tongue squamous cell carcinoma
classification using Raman spectroscopy. Photodiagnosis and Photodynamic Therapy 2019,
26, 430-435.
25.
Jeng, M. J.; Sharma, M.; Sharma, L.; Chao, T. Y.; Huang, S. F.; Chang, L. B.; Wu,
S. L.; Chow, L., Raman Spectroscopy Analysis for Optical Diagnosis of Oral Cancer Detection.
Journal of Clinical Medicine 2019, 8 (9).
26.
Cals, F. L. J.; Schut, T. C. B.; Caspers, P. J.; de Jong, R. J. B.; Koljenovic, S.; Puppels,
G. J., Raman spectroscopic analysis of the molecular composition of oral cavity squamous cell
carcinoma and healthy tongue tissue. Analyst 2018, 143 (17), 4090-4102.
27.
Cals, F. L. J.; Koljenovic, S.; Hardillo, J. A.; de Jong, R. J. B.; Schut, T. C. B.;
Puppels, G. J., Development and validation of Raman spectroscopic classification models to

Cancers 2020, 12, x FOR PEER REVIEW

18 of 19

discriminate tongue squamous cell carcinoma from non-tumorous tissue. Oral Oncology 2016,
60, 41-47.
28.
Barroso, E. M.; ten Hove, I.; Schut, T. C. B.; Mast, H.; van Lanschot, C. G. F.; Smits,
R. W. H.; Caspers, P. J.; Verdijk, R.; Hegt, V. N.; de Jong, R. J. B.; Wolvius, E. B.; Puppels,
G. J.; Koljenovic, S., Raman spectroscopy for assessment of bone resection margins in
mandibulectomy for oral cavity squamous cell carcinoma. European Journal of Cancer 2018,
92, 77-87.
29.
Cals, F. L. J.; Schut, T. C. B.; Hardillo, J. A.; de Jong, R. J. B.; Koljenovic, S.;
Puppels, G. J., Investigation of the potential of Raman spectroscopy for oral cancer detection
in surgical margins. Laboratory Investigation 2015, 95 (10), 1186-1196.
30.
Movasaghi, Z.; Rehman, S.; Rehman, I. U., Raman spectroscopy of biological tissues.
Applied Spectroscopy Reviews 2007, 42 (5), 493-541.
31.
Kalluri, R.; Weinberg, R. A., The basics of epithelial-mesenchymal transition. Journal
of Clinical Investigation 2009, 119 (6), 1420-1428.
32.
Speight, P. M., Update on Oral Epithelial Dysplasia and Progression to Cancer. Head
and Neck Pathology 2007, 1 (1), 61-66.
33.
Sahu, A.; Deshmukh, A.; Ghanate, A. D.; Singh, S. P.; Chaturvedi, P.; Krishna, C.
M., Raman Spectroscopy of Oral Buccal Mucosa: A Study on Age-Related Physiological
Changes and Tobacco-Related Pathological Changes. Technology in Cancer Research &
Treatment 2012, 11 (6), 529-541.
34.
Depciuch, J.; Sowa-Kucma, M.; Nowak, G.; Dudek, D.; Siwek, M.; Styczen, K.;
Parlinska-Wojtan, M., Phospholipid-protein balance in affective disorders: Analysis of human
blood serum using Raman and FTIR spectroscopy. A pilot study. Journal of Pharmaceutical
and Biomedical Analysis 2016, 131, 287-296.
35.
Singh, S. P.; Deshmukh, A.; Chaturvedi, P.; Krishna, C. M., In vivo Raman
spectroscopic identification of premalignant lesions in oral buccal mucosa. Journal of
Biomedical Optics 2012, 17 (10).
36.
Rashid, N.; Nawaz, H.; Poon, K. W. C.; Bonnier, F.; Bakhiet, S.; Martin, C.;
O'Leary, J. J.; Byrne, H. J.; Lyng, F. M., Raman microspectroscopy for the early detection of
pre-malignant changes in cervical tissue. Experimental and Molecular Pathology 2014, 97 (3),
554-564.
37.
Sorsa, T.; Tjaderhane, L.; Salo, T., Matrix metalloproteinases (MMPs) in oral diseases.
Oral Diseases 2004, 10 (6), 311-318.
38.
Mashhadiabbas, F.; Fayazi-Boroujeni, M., Correlation of vascularization and
inflammation with severity of oral leukoplakia. Iranian Journal of Pathology 2017, 12 (3),
225-230.
39.
Negus, R. P. M.; Stamp, G. W. H.; Hadley, J.; Balkwill, F. R., Quantitative assessment
of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C
chemokines. American Journal of Pathology 1997, 150 (5), 1723-1734.
40.
Talmadge, J. E., Immune cell infiltration of primary and metastatic lesions:
Mechanisms and clinical impact. Seminars in Cancer Biology 2011, 21 (2), 131-138.
41.
Takahashi, H.; Ogata, H.; Nishigaki, R.; Broide, D. H.; Karin, M., Tobacco Smoke
Promotes Lung Tumorigenesis by Triggering IKK beta- and JNK1-Dependent Inflammation.
Cancer Cell 2010, 17 (1), 89-97.
42.
Feller, L.; Altini, M.; Lemmer, J., Inflammation in the context of oral cancer. Oral
Oncology 2013, 49 (9), 887-892.
43.
Ibrahim, O.; Maguire, A.; Meade, A. D.; Flint, S.; Toner, M.; Byrne, H. J.; Lyng, F.
M., Improved protocols for pre-processing Raman spectra of formalin fixed paraffin preserved
tissue sections. Analytical Methods 2017, 9 (32), 4709-4717.

Cancers 2020, 12, x FOR PEER REVIEW

19 of 19

44.
Mandrekar, J. N., Receiver Operating Characteristic Curve in Diagnostic Test
Assessment. Journal of Thoracic Oncology 2010, 5 (9), 1315-1316.
45.
Cankovic, M.; Ilic, M. P.; Vuckovic, N.; Bokor-Bratic, M., The histological
characteristics of clinically normal mucosa adjacent to oral cancer. Journal of Cancer Research
and Therapeutics 2013, 9 (2), 240-244.

